AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14979503 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung volume reduction surgery
Number of subjects: 60
Study 14979503 — intervention group
Group type: COMPARATOR
Intervention: Rehabilitation
Number of subjects: 60
Study 11481684 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Sleep Deprivation (TSD)
Number of subjects: 15
Study 11481684 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial Sleep Deprivation (PSD)
Number of subjects: 15
Study 11481684 — intervention group
Group type: COMPARATOR
Intervention: Normal Sleep (S)
Number of subjects: 15
Study 9272342 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular pertussis vaccines
Number of subjects: 0
Study 9272342 — intervention group
Group type: COMPARATOR
Intervention: Whole-cell vaccine
Number of subjects: 0
Study 9272342 — intervention group
Group type: COMPARATOR
Intervention: Placebo-controlled, double-blind trials
Number of subjects: 0
Study 8440856 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted risk abatement intervention (TI) strategy
Number of subjects: 0
Study 8440856 — intervention group
Group type: COMPARATOR
Intervention: Usual care plus social visits (SV)
Number of subjects: 0
Study 3819288 — intervention group
Group type: EXPERIMENTAL
Intervention: Corning 527 lens
Number of subjects: 103
Study 3819288 — intervention group
Group type: COMPARATOR
Intervention: Plano lens
Number of subjects: 103
Study 3819288 — intervention group
Group type: COMPARATOR
Intervention: Equivalent neutral density filter
Number of subjects: 103
Study 29127842 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide (0.5mg/day)
Number of subjects: 55
Study 29127842 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 55
Study 27661022 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry cupping on point P6 with activation of intermittent negative pressure
Number of subjects: 206
Study 27661022 — intervention group
Group type: COMPARATOR
Intervention: Sham cupping without activation of negative pressure
Number of subjects: 206
Study 24987051 — intervention group
Group type: EXPERIMENTAL
Intervention: EDTA chelation therapy
Number of subjects: 1708
Study 24987051 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1708
Study 22456591 — intervention group
Group type: EXPERIMENTAL
Intervention: Video self-observation (viewing themselves when ill)
Number of subjects: 40
Study 22456591 — intervention group
Group type: COMPARATOR
Intervention: Observation of others (viewing a same-sex actor displaying psychotic symptoms)
Number of subjects: 40
Study 20202941 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper limb exercises at 65% workload
Number of subjects: 24
Study 20202941 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper limb exercises at 80% workload
Number of subjects: 24
Study 20202941 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper limb exercises at 50% workload
Number of subjects: 24
Study 18237361 — intervention group
Group type: COMPARATOR
Intervention: Epoetin alfa
Number of subjects: 18
Study 15971396 — intervention group
Group type: EXPERIMENTAL
Intervention: Lay health worker intervention on 106 intervention farms
Number of subjects: 164
Study 15971396 — intervention group
Group type: COMPARATOR
Intervention: Control group on 105 control farms
Number of subjects: 164
Study 12357162 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal adenosine 0.5 mg
Number of subjects: 30
Study 12357162 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal adenosine 2.0 mg
Number of subjects: 30
Study 12357162 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 30
Study 12357162 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline 5 mg/kg
Number of subjects: 30
Study 14557958 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-valent pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine (PncOMPC)
Number of subjects: 1666
Study 14557958 — intervention group
Group type: COMPARATOR
Intervention: Control vaccine (hepatitis B vaccine)
Number of subjects: 1666
Study 9578008 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 16
Study 9578008 — intervention group
Group type: COMPARATOR
Intervention: High-dose barbiturates
Number of subjects: 16
Study 7644238 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular ketorolac (1 mg/kg)
Number of subjects: 87
Study 7644238 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 87
Study 2526633 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant hepatitis B vaccine (HBVax II, MSD, 5 micrograms)
Number of subjects: 40
Study 2526633 — intervention group
Group type: COMPARATOR
Intervention: Plasma derived hepatitis B vaccine (HBVax, MSD, 10 micrograms)
Number of subjects: 40
Study 136668 — intervention group
Group type: EXPERIMENTAL
Intervention: Mianserin hydrochloride (20 mg three times daily)
Number of subjects: 0
Study 136668 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 0
Study 136668 — intervention group
Group type: EXPERIMENTAL
Intervention: Mianserin hydrochloride
Number of subjects: 0
Study 31215721 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted intervention
Number of subjects: 44820
Study 31215721 — intervention group
Group type: COMPARATOR
Intervention: Enhanced intervention
Number of subjects: 44820
Study 28625367 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-guideline period (after 2007 AHA guidelines)
Number of subjects: 3748
Study 28625367 — intervention group
Group type: COMPARATOR
Intervention: Pre-guideline period (before 2007 AHA guidelines)
Number of subjects: 3748
Study 26578109 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced case management of asthma and COPD patients through strengthening of PHC facilities
Number of subjects: 734
Study 26578109 — intervention group
Group type: COMPARATOR
Intervention: Standard care practices
Number of subjects: 734
Study 22702846 — intervention group
Group type: COMPARATOR
Intervention: Etanercept monotherapy
Number of subjects: 30
Study 22702846 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination etanercept and NB-UVB phototherapy
Number of subjects: 30
Study 22702846 — intervention group
Group type: COMPARATOR
Intervention: Both groups (etanercept monotherapy and combination therapy)
Number of subjects: 30
Study 21785174 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF) and erythropoietin (EPO) based intracoronary infusion of peripheral blood stem cells (PBSCs) after 5 days of G-CSF administration and EPO at the time of PBSCs injection
Number of subjects: 18
Study 19111789 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysterectomy
Number of subjects: 237
Study 19111789 — intervention group
Group type: COMPARATOR
Intervention: Endometrial ablation
Number of subjects: 237
Study 19111789 — intervention group
Group type: EXPERIMENTAL
Intervention: Effective surgical treatment costing $40,000
Number of subjects: 237
Study 16458799 — intervention group
Group type: EXPERIMENTAL
Intervention: Polygluconate co‐polymer (PGACP group, n = 20)
Number of subjects: 40
Study 16458799 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐reinforced poly‐L‐lactic acid polymer (PLLA group, n = 20)
Number of subjects: 40
Study 16458799 — intervention group
Group type: COMPARATOR
Intervention: Both groups (PGACP and PLLA)
Number of subjects: 40
Study 16458799 — intervention group
Group type: EXPERIMENTAL
Intervention: PLLA group
Number of subjects: 40
Study 16458799 — intervention group
Group type: EXPERIMENTAL
Intervention: PGACP group
Number of subjects: 40
Study 15496639 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine 50 mg daily for 6 days
Number of subjects: 18
Study 15496639 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 11783366 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH‐a long protocol (0.9 mg/day nasal spray starting on day 21)
Number of subjects: 109
Study 11783366 — intervention group
Group type: COMPARATOR
Intervention: GnRH‐a short protocol (0.45 mg/day nasal spray starting on day 2)
Number of subjects: 109
Study 11783366 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH‐a long protocol and short protocol
Number of subjects: 109
Study 9281927 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management program
Number of subjects: 55
Study 8337991 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasone butyrate 0.1% eye drops, two drops each eye, t.i.d. for 10 days
Number of subjects: 30
Study 8337991 — intervention group
Group type: COMPARATOR
Intervention: Placebo eye drops, two drops each eye, t.i.d. for 10 days
Number of subjects: 30
Study 3688151 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep Pressure Touch (DPT)
Number of subjects: 23
Study 3688151 — intervention group
Group type: COMPARATOR
Intervention: Confinement without DPT (Control)
Number of subjects: 23
Study 30153359 — intervention group
Group type: EXPERIMENTAL
Intervention: Simtuzumab 75 mg
Number of subjects: 234
Study 30153359 — intervention group
Group type: EXPERIMENTAL
Intervention: Simtuzumab 125 mg
Number of subjects: 234
Study 30153359 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 234
Study 30153359 — intervention group
Group type: EXPERIMENTAL
Intervention: Simtuzumab 75 mg and 125 mg
Number of subjects: 234
Study 30153359 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (all groups)
Number of subjects: 234
Study 30153359 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced fibrosis
Number of subjects: 234
Study 30153359 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher alkaline phosphatase
Number of subjects: 234
Study 30153359 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher enhanced liver fibrosis score
Number of subjects: 234
Study 30153359 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 234
Study 28060063 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2 g/d of a triglyceride formulation of oral omega-3 fatty acids for 12 weeks
Number of subjects: 60
Study 28060063 — intervention group
Group type: COMPARATOR
Intervention: 400 mg/d vitamin E for 12 weeks
Number of subjects: 60
Study 26209038 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin (50 mg/day)
Number of subjects: 30
Study 26209038 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride (1 mg/day) - Control
Number of subjects: 30
Study 24180000 — intervention group
Group type: EXPERIMENTAL
Intervention: abacavir, zidovudine, lamivudine (arm A)
Number of subjects: 730
Study 24180000 — intervention group
Group type: EXPERIMENTAL
Intervention: lopinavir–ritonavir, zidovudine–lamivudine (arm B)
Number of subjects: 730
Study 24180000 — intervention group
Group type: COMPARATOR
Intervention: nevirapine–zidovudine–lamivudine (Obs arm)
Number of subjects: 730
Study 24180000 — intervention group
Group type: EXPERIMENTAL
Intervention: All arms
Number of subjects: 730
Study 21140383 — intervention group
Group type: EXPERIMENTAL
Intervention: 240 mg of EGb 761 once daily for 24 weeks
Number of subjects: 410
Study 21140383 — intervention group
Group type: COMPARATOR
Intervention: Placebo once daily for 24 weeks
Number of subjects: 410
Study 19014338 — intervention group
Group type: EXPERIMENTAL
Intervention: docetaxel/estramustine
Number of subjects: 0
Study 19014338 — intervention group
Group type: COMPARATOR
Intervention: zoledronic acid
Number of subjects: 0
Study 17233285 — intervention group
Group type: EXPERIMENTAL
Intervention: Free Bone Graft (FBG)
Number of subjects: 65
Study 17233285 — intervention group
Group type: COMPARATOR
Intervention: PEEK Cage
Number of subjects: 65
Study 15596591 — intervention group
Group type: EXPERIMENTAL
Intervention: Submacular surgery
Number of subjects: 1015
Study 15596591 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 1015
Study 11449954 — intervention group
Group type: EXPERIMENTAL
Intervention: Solvent/detergent-treated intramuscular immunoglobulin
Number of subjects: 36
Study 11449954 — intervention group
Group type: COMPARATOR
Intervention: Standard intramuscular immunoglobulin
Number of subjects: 36
Study 9610964 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous propafenone (2 mg/kg for 10 min)
Number of subjects: 156
Study 9610964 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study 7946873 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetanic stimulation at 25% of control twitch height (T0)
Number of subjects: 45
Study 7946873 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetanic stimulation at 50% of control twitch height (T0)
Number of subjects: 45
Study 7946873 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetanic stimulation at 75% of control twitch height (T0)
Number of subjects: 45
Study 3260083 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 mg propofol/kg per minute
Number of subjects: 40
Study 3260083 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.10 mg propofol/kg per minute
Number of subjects: 40
Study 3260083 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15 mg propofol/kg per minute
Number of subjects: 40
Study 3260083 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.20 mg propofol/kg per minute
Number of subjects: 40
Study 3260083 — intervention group
Group type: EXPERIMENTAL
Intervention: Total propofol consumption
Number of subjects: 40
Study 3260083 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery time
Number of subjects: 40
Study 3260083 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial blood pressure
Number of subjects: 40
Study 3260083 — intervention group
Group type: EXPERIMENTAL
Intervention: Side effects
Number of subjects: 40
Study 29783942 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning and Coping strategies (LC) plus Cardiac Rehabilitation (CR)
Number of subjects: 244
Study 29783942 — intervention group
Group type: COMPARATOR
Intervention: Cardiac Rehabilitation (CR) alone
Number of subjects: 244
Study 28221177 — intervention group
Group type: EXPERIMENTAL
Intervention: Semirigid waved rod systems
Number of subjects: 96
Study 28221177 — intervention group
Group type: COMPARATOR
Intervention: Traditional rigid straight stiff rod systems
Number of subjects: 96
Study 26333513 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant sterols (2 g PS/d)
Number of subjects: 63
Study 26333513 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 24194839 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-pneumatic Anti-Shock Garment (NASG) applied before transport to referral hospitals (RHs)
Number of subjects: 880
Study 24194839 — intervention group
Group type: COMPARATOR
Intervention: Standard obstetric hemorrhage/shock protocols
Number of subjects: 880
Study 21962416 — intervention group
Group type: EXPERIMENTAL
Intervention: Upright posture (90 minutes sitting and treadmill walking)
Number of subjects: 9
Study 21962416 — intervention group
Group type: COMPARATOR
Intervention: Supine posture (90 minutes recumbency)
Number of subjects: 9
Study 18178379 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemented hypokinetic subjects (SHKSs) with daily supplementation of 0.7 mmol of calcium lactate per kilogram of body weight
Number of subjects: 40
Study 18178379 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsupplemented hypokinetic subjects (UHKSs)
Number of subjects: 40
Study 18178379 — intervention group
Group type: COMPARATOR
Intervention: Supplemented active control subjects (SACSs)
Number of subjects: 40
Study 18178379 — intervention group
Group type: COMPARATOR
Intervention: Unsupplemented active control subjects (UACSs)
Number of subjects: 40
Study 16813479 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythmic stabilization training
Number of subjects: 86
Study 16813479 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of isotonic exercises
Number of subjects: 86
Study 16813479 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 86
Study 12708129 — intervention group
Group type: COMPARATOR
Intervention: Oral medication (Group I)
Number of subjects: 80
Study 12708129 — intervention group
Group type: COMPARATOR
Intervention: Insulin treatment (Group II)
Number of subjects: 80
Study 12708129 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal controls
Number of subjects: 80
Study 10759770 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART alone
Number of subjects: 0
Study 10759770 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART + IL-2
Number of subjects: 0
Study 10759770 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 10759770 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART alone or HAART + IL-2
Number of subjects: 0
Study 8621989 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 3837
Study 8621989 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol with aspirin and/or coronary artery surgery
Number of subjects: 3837
Study 8621989 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol without aspirin and/or coronary artery surgery
Number of subjects: 3837
Study 8621989 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3837
Study 1423088 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual mammography and physical examination (MP group)
Number of subjects: 39405
Study 1423088 — intervention group
Group type: COMPARATOR
Intervention: Annual physical examination only (PO group)
Number of subjects: 39405
Study 3891769 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation (complete cessation for 14 subjects)
Number of subjects: 66
Study 3891769 — intervention group
Group type: COMPARATOR
Intervention: Control group (33 matched controls continuing smoking)
Number of subjects: 66
Study 31443663 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Decision Support System (CDSS) prompt
Number of subjects: 15222
Study 31443663 — intervention group
Group type: COMPARATOR
Intervention: No CDSS prompt (Control)
Number of subjects: 15222
Study 30231484 — intervention group
Group type: EXPERIMENTAL
Intervention: Danggui Buxue Tang (DBT) supplementation
Number of subjects: 36
Study 30231484 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 28768071 — intervention group
Group type: COMPARATOR
Intervention: Hyperbaric oxygen (HBO₂)
Number of subjects: 71
Study 28768071 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 71
Study 24183249 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromagnetic (EM) navigator guidance without fluoroscopic support
Number of subjects: 15
Study 24183249 — intervention group
Group type: COMPARATOR
Intervention: Conventional fluoroscopic guidance
Number of subjects: 15
Study 21831719 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed-containing arms
Number of subjects: 2296
Study 21831719 — intervention group
Group type: COMPARATOR
Intervention: Non-pemetrexed-containing arms
Number of subjects: 2296
Study 21831719 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed exposure
Number of subjects: 2296
Study 19597910 — intervention group
Group type: EXPERIMENTAL
Intervention: Strontium ranelate
Number of subjects: 0
Study 17548693 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum alpha‐tocopherol supplementation (50 mg daily for 5‐8 years)
Number of subjects: 29133
Study 17548693 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher serum alpha‐tocopherol
Number of subjects: 29133
Study 17548693 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementation with either alpha‐tocopherol or beta‐carotene
Number of subjects: 29133
Study 17548693 — intervention group
Group type: COMPARATOR
Intervention: Dietary tocopherols and tocotrienols
Number of subjects: 29133
Study 15233282 — intervention group
Group type: EXPERIMENTAL
Intervention: Disopyramide (6 mg/kg)
Number of subjects: 35
Study 15233282 — intervention group
Group type: COMPARATOR
Intervention: Mexiletine (4 mg/kg)
Number of subjects: 35
Study 15233282 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilsicainide (4 mg/kg)
Number of subjects: 35
Study 11407971 — intervention group
Group type: EXPERIMENTAL
Intervention: Topically applied vitamin C
Number of subjects: 0
Study 11407971 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9203234 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (mean dose at endpoint: 5.9 mg/day)
Number of subjects: 945
Study 9203234 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 945
Study 11767424 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ml of physiological saline injection (Group A)
Number of subjects: 70
Study 11767424 — intervention group
Group type: COMPARATOR
Intervention: No injection (Group B)
Number of subjects: 70
Study 2888795 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol
Number of subjects: 20
Study 2888795 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 20
Study 2888795 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol and Metoprolol
Number of subjects: 20
Study 31959341 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX4-bevacizumab
Number of subjects: 2867
Study 31959341 — intervention group
Group type: EXPERIMENTAL
Intervention: XELOX-bevacizumab
Number of subjects: 2867
Study 31959341 — intervention group
Group type: COMPARATOR
Intervention: FOLFOX4
Number of subjects: 2867
Study 29443425 — intervention group
Group type: COMPARATOR
Intervention: Low AAC (AAC24 score 0 or 1)
Number of subjects: 1052
Study 29443425 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate AAC (AAC24 score 2-5)
Number of subjects: 1052
Study 29443425 — intervention group
Group type: EXPERIMENTAL
Intervention: High AAC (AAC24 score ≥6)
Number of subjects: 1052
Study 29443425 — intervention group
Group type: EXPERIMENTAL
Intervention: High AAC
Number of subjects: 1052
Study 29443425 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate AAC
Number of subjects: 1052
Study 27184606 — intervention group
Group type: EXPERIMENTAL
Intervention: Ex-PRESS implantation
Number of subjects: 64
Study 27184606 — intervention group
Group type: COMPARATOR
Intervention: Trabeculectomy
Number of subjects: 64
Study 25322078 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD breathlessness manual (CM)
Number of subjects: 222
Study 25322078 — intervention group
Group type: COMPARATOR
Intervention: Information booklets (IB)
Number of subjects: 222
Study 24365207 — intervention group
Group type: EXPERIMENTAL
Intervention: nCPAP (nasal CPAP)
Number of subjects: 73
Study 24365207 — intervention group
Group type: COMPARATOR
Intervention: FmCPAP (full face mask CPAP)
Number of subjects: 73
Study 20570240 — intervention group
Group type: EXPERIMENTAL
Intervention: Subconjunctival injection of 0.02% MMC 1 month before bare scleral excision
Number of subjects: 82